疫苗学《Vaccines》——6th Edition by (美)普洛特金

rojjer

Vaccines, 6th Edition

/ }5 [# b9 \$ F2 o$ F, a' ~/ CApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.

http://yun.baidu.com/share/link?shareid=2079860221&uk=3810996606
& X1 l! F+ @1 L/ J% a
SECTION 1: General aspects of vaccination
1 A short history of vaccination 1
# Y5 J- |: w" K) e2 Vaccine immunology 14
3 The vaccine industry 33
4 Vaccine manufacturing 44
5 Evolution of adjuvants across the centuries 58
6 Vaccine additives and manufacturing residuals in the United States:
% O4 `+ O3 Q6 j/ Blicensed vaccines 71
7 Passive immunization 80
8 General immunization practices 88
1 ~! r* k7 i. ?" \3 A7 ASECTION 2: Licensed vaccines
/ W5 R& U/ _* Y% S& ^/ n+ A9 Adenovirus vaccines 113
10 Anthrax vaccines 127
11 Cholera vaccines 141
  t4 }3 ]# x9 x- I6 r7 J12 Diphtheria toxoid 153
13 Haemophilus influenzae vaccines 167
14 Hepatitis A vaccines 183
15 Hepatitis B vaccines 205
9 k6 M! f$ `! _6 W0 [% g16 Human papillomavirus vaccines 235
3 `  l0 ~, w0 L, T8 w: [17 Inactivated influenza vaccines 257
18 Influenza vaccine-live 294
19 Japanese encephalitis vaccines 312
20 Measles vaccines 352
21 Meningococcal vaccines 388
$ I3 ~/ n/ M5 @0 [0 Y) M0 X22 Mumps vaccine 419
% U, O. G. L' [+ n" F5 G9 Y23 Pertussis vaccines . 447
24 Plague vaccines 493
25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
! F( r7 o; A1 f3 J: F3 \% m26 Pneumococcal polysaccharide vaccines 542
/ {; k2 E9 \# ~2 X& L27 Poliovirus vaccine-inactivated . 573
0 V7 ]) V9 J! C  m! {: s28 Poliovirus vaccine-live 598
4 B* M4 `6 `3 z. k29 Rabies vaccines .646
& A, m* ?' p" |/ z5 J+ U30 Rotavirus vaccines . 669
31 Rubella vaccine 688
32 Smallpox and vaccinia 718
" i! u0 H5 ^7 P7 Q33 Tetanus toxoid 746
34 Tick-borne encephalitis virus vaccines 773
/ L7 Y: F2 U0 {- H0 F4 I- P; z35 Tuberculosis vaccines 789
4 X4 c$ K5 p) |36 Typhoid fever vaccines 812
( g! |( V' m! Z37 Varicella vaccine 837
38 Yellow fever vaccine 870
. L2 b# y  |; Y$ i. m3 j39 Zoster vaccine 969
: r8 X. A& }" S2 o$ I' w40 Combination vaccines 981
0 Y3 n* P0 ~" h+ X+ B& zSECTION 3: Vaccines in development and new vaccine strategies
41 Biodefense and special pathogen vaccines 1008
. p5 D4 P  J9 G8 O4 P  y. d42 Therapeutic cancer vaccines 1018
$ i) S5 P  F' g5 t; c+ \43 Cytomegalovirus vaccines 1032
44 Dengue vaccines 1042
45 Diarrhea caused by bacteria 1052
46 Ebola vaccine 1060
/ O# Y6 \* E7 G+ k$ s4 K$ t47 Epstein-Barr virus vaccines 1068
5 m2 m- ~6 r6 R% F9 Y48 Hepatitis C vaccines 1074
49 Hepatitis E vaccines 1085
50 Herpes simplex virus vaccines 1090
51 Human immunodeficiency virus vaccines 1097
52 Lyme disease vaccines 1122
$ R5 b% s# I0 J53 Malaria vaccines 1133
3 J- s% x% D7 Z  m5 _54 Noninfectious disease vaccines 1138
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
9 G7 W1 Q* d* o- L8 y3 ~4 I56 Parasitic disease vaccines 1154
57 Staphylococcus aureus vaccines 1161
, K, Q) j" D- {( w$ M& U58 Streptococcus group A vaccines 1169
59 Streptococcus group B vaccines 1176
: j. H2 [; a  o  c! U- W: s# m60 Technologies for making new vaccines 1182
61 Alternative vaccine delivery methods 1200
/ t) j2 ~& c* ?: s$ L62 The development of gene-based vectors for immunization 1232
SECTION 4: Vaccination of special groups
& q' N4 C. F6 j# E" n' d* y7 L( L63 Vaccination of immunocompromised hosts 1243
64 Vaccination of human immunodeficiency virus-infected persons 1257
3 x/ o) n4 [9 F) o65 Vaccines for international travel 1270
7 R9 c: |8 E8 P. O0 q* [66 Vaccines for health care personnel 1290
SECTION 5: Public health and regulatory issues
4 W! q" z/ s3 |4 W7 `$ S; e5 Z0 U67 Immunization in the United States 1310
68 Immunization in Europe . 1334
5 d  |4 U/ D# F' o6 P) T69 Immunization in the Asia-Pacific region 1353
70 Immunization in developing countries 1369
9 x; w: T0 r5 I, X3 R6 z: f! ]! s% s/ S71 Community immunity 1395
72 Economic analyses of vaccine policies 1413
73 Regulation and testing of vaccines 1427
( u" M2 l3 y2 F& `; @5 u5 z0 F6 p74 Regulation of vaccines in Europe 1447
9 V1 h7 s! |& h75 Regulation of vaccines in developing countries 1454
76 Vaccine safety 1464
77 Legal issues . 1481
78 Ethics 1508


0 u. c; k0 e- d& s

casarett

Vaccines, 6e, 2012
, E: Q  K4 A& f
- P+ n8 U% R' z& i8 G( A0 @Hardcover: 1570 pages
Publisher: Saunders; 6 edition (October 30, 2012)
8 W1 E! s+ T% K/ dLanguage: English
. e9 N* C- w4 V, CISBN-10: 1455700908
" \  L; f% h5 i. L: W' n& NSize: 52.3mb (original pdf)

2013 BMA Medical Book Awards Highly Commended in Public Health!
! o& b; m2 D3 b$ `/ m/ ZApply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice!
- I& \8 ^/ o3 y3 p  [
Gain a complete understanding of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues.
Update your knowledge of both existing vaccines and vaccines currently in the research and development stage.
, T  e1 F, j  Y+ o* d" aGet complete answers on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies.
Analyze the cost-benefit and cost-effectiveness of different vaccine options.
- s) S, U2 k% J  P. b% K7 ^Clearly visualize concepts and objective data through an abundance of tables and figures.
Perform seamless searches of the complete text online, access all the references, and download all the images at www.expertconsult.com.
6 I. B- M0 q( Q6 A+ U; x6 }; WMake optimal use of the latest vaccines for pneumococcal disease, rotavirus, human papillomavirus, herpes zoster, meningococcal disease, and much more.
9 s9 O3 v- r8 f: B: P% E" Y& x  ~Stay at the forefront of new developments with completely updated chapters on malaria and HIV vaccines, a new chapter on vaccine regulations across the world, and many other revisions throughout.

+ N( _+ ]9 v, dDownload link: http://pan.baidu.com/s/1i5NxwLR
Code for downloading: dv96
( f) E5 I$ o) A$ k. [

rojjer

2 \! h" t7 ^' o4 X6 W) xVaccines, 6th Edition

Apply the latest vaccination knowledge with a reference that Bill Gates calls "an indispensable guide to the enhancement of the well-being of our world." Inside Vaccines, you’ll find comprehensive and current coverage of every aspect of vaccination, from the development of each vaccine to its use in reducing disease. This medical reference book offers the expert information you need to apply the very latest techniques and information in your practice.

) g( \, C7 X. Z; r- I  ghttp://yun.baidu.com/share/link? ... 1&uk=3810996606

+ m/ r! G/ g7 p% SSECTION 1: General aspects of vaccination
+ u" u8 q& W* I& j1 A short history of vaccination 1
9 W8 _, [. H- [+ x' E7 X, M& H2 Vaccine immunology 14
3 The vaccine industry 33
7 [- q. a0 R/ ?4 F0 G, N4 Vaccine manufacturing 44
5 Evolution of adjuvants across the centuries 58
% [3 }; D" L7 U( B6 Vaccine additives and manufacturing residuals in the United States:
licensed vaccines 71
7 Passive immunization 80
0 ~. @6 ~9 b! Y1 Y9 \. a8 General immunization practices 88
SECTION 2: Licensed vaccines
9 Adenovirus vaccines 113
' ~: J  c' d+ j0 Z& N10 Anthrax vaccines 127
11 Cholera vaccines 141
4 |& v9 ~& m+ A; k( T/ o% i3 o12 Diphtheria toxoid 153
( @0 S' Y8 S1 l1 Z  w8 z2 ~13 Haemophilus influenzae vaccines 167
14 Hepatitis A vaccines 183
) @, b. o4 U/ K! S+ b+ c5 C15 Hepatitis B vaccines 205
+ F/ b; m8 s. h8 ^+ p& T/ W$ Q1 e16 Human papillomavirus vaccines 235
( e  q! |. _; z2 w# t7 ~17 Inactivated influenza vaccines 257
3 D7 e$ `7 {% n' c5 p. p18 Influenza vaccine-live 294
19 Japanese encephalitis vaccines 312
* @5 M- T+ `) L: k20 Measles vaccines 352
. p* L6 J1 s! e$ d" p7 q21 Meningococcal vaccines 388
22 Mumps vaccine 419
23 Pertussis vaccines . 447
, |' x- P8 _7 m+ J, t* `24 Plague vaccines 493
# Q6 B6 \& A( o25 Pneumococcal conjugate vaccine and pneumococcal common protein vaccines 504
26 Pneumococcal polysaccharide vaccines 542
& ~( T2 y7 z9 [, J27 Poliovirus vaccine-inactivated . 573
( a& `* K" E4 C. i' G28 Poliovirus vaccine-live 598
29 Rabies vaccines .646
30 Rotavirus vaccines . 669
8 _7 D* c7 l+ V2 ?( o9 M" n31 Rubella vaccine 688
2 o% E! v5 C2 O32 Smallpox and vaccinia 718
% s5 a* o% r. ^* y# Q% E" d6 T" }7 o, E33 Tetanus toxoid 746
& \% w/ s$ N5 h& }34 Tick-borne encephalitis virus vaccines 773
5 M- ?. _; O0 W, i35 Tuberculosis vaccines 789
! t$ w/ }4 l6 e36 Typhoid fever vaccines 812
5 c5 B- w+ ~' l* y# q37 Varicella vaccine 837
9 r9 M* X$ Z& C% W5 n  j38 Yellow fever vaccine 870
39 Zoster vaccine 969
& Y, A6 Q: r% p- `! ^6 \% g$ _40 Combination vaccines 981
SECTION 3: Vaccines in development and new vaccine strategies
5 Z5 x1 \) K7 c1 [* n41 Biodefense and special pathogen vaccines 1008
42 Therapeutic cancer vaccines 1018
43 Cytomegalovirus vaccines 1032
44 Dengue vaccines 1042
# ]" V+ R5 g9 r  F  G45 Diarrhea caused by bacteria 1052
46 Ebola vaccine 1060
9 ^+ y3 A: a" {* k8 Y. N47 Epstein-Barr virus vaccines 1068
! D9 P! w7 s- w% K( k3 F48 Hepatitis C vaccines 1074
49 Hepatitis E vaccines 1085
( A' K  P  Q" H2 f+ o50 Herpes simplex virus vaccines 1090
+ N. n7 q+ o" v51 Human immunodeficiency virus vaccines 1097
52 Lyme disease vaccines 1122
% s9 \( G! \  ]2 ]5 K4 h1 p( K53 Malaria vaccines 1133
! W, ~' L9 u. U, k9 y& l54 Noninfectious disease vaccines 1138
55 Respiratory syncytial virus and parainfluenza virus vaccines 1146
56 Parasitic disease vaccines 1154
57 Staphylococcus aureus vaccines 1161
58 Streptococcus group A vaccines 1169
59 Streptococcus group B vaccines 1176
60 Technologies for making new vaccines 1182
61 Alternative vaccine delivery methods 1200
62 The development of gene-based vectors for immunization 1232
SECTION 4: Vaccination of special groups
. S9 p* \9 L" y. a6 ?, z& i2 z8 N63 Vaccination of immunocompromised hosts 1243
64 Vaccination of human immunodeficiency virus-infected persons 1257
65 Vaccines for international travel 1270
- C; |: i" m- P; z' H( y$ B1 {4 x66 Vaccines for health care personnel 1290
- O- q8 k8 D: U; k1 D& oSECTION 5: Public health and regulatory issues
9 L% n+ f7 D* H7 C3 u3 t+ M67 Immunization in the United States 1310
68 Immunization in Europe . 1334
+ K# Q  @, ^$ \6 s69 Immunization in the Asia-Pacific region 1353
% C/ y& P7 ]3 @. y# L% J70 Immunization in developing countries 1369
! P+ h% F8 F' j6 S; }71 Community immunity 1395
72 Economic analyses of vaccine policies 1413
: R( r( ^: @7 O, I' l0 X73 Regulation and testing of vaccines 1427
, e2 e. s+ r9 E0 m# n74 Regulation of vaccines in Europe 1447
75 Regulation of vaccines in developing countries 1454
( e' v: q9 S) P& N- v- u# @76 Vaccine safety 1464
77 Legal issues . 1481
78 Ethics 1508

$ v% I* V7 U7 m# w6 X) ^1 }, U

zhpu2008

怎么看不到相关下载呀

zhpu2008

谢谢分享

salina

非常感谢